NZ552508A - Treatment of cancer with pharmaceutical agents together with anti-Hsp 90 antibodies - Google Patents

Treatment of cancer with pharmaceutical agents together with anti-Hsp 90 antibodies

Info

Publication number
NZ552508A
NZ552508A NZ552508A NZ55250805A NZ552508A NZ 552508 A NZ552508 A NZ 552508A NZ 552508 A NZ552508 A NZ 552508A NZ 55250805 A NZ55250805 A NZ 55250805A NZ 552508 A NZ552508 A NZ 552508A
Authority
NZ
New Zealand
Prior art keywords
ser
gly
antibody
cancer
leukaemia
Prior art date
Application number
NZ552508A
Other languages
English (en)
Inventor
James Peter Burnie
Ruth Christine Matthews
Tracey Carter
Original Assignee
Neutec Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0414885A external-priority patent/GB0414885D0/en
Priority claimed from GB0420845A external-priority patent/GB0420845D0/en
Priority claimed from GB0503566A external-priority patent/GB0503566D0/en
Application filed by Neutec Pharma Ltd filed Critical Neutec Pharma Ltd
Priority claimed from PCT/GB2005/002545 external-priority patent/WO2006003384A1/en
Publication of NZ552508A publication Critical patent/NZ552508A/en

Links

Landscapes

  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
NZ552508A 2004-07-02 2005-06-30 Treatment of cancer with pharmaceutical agents together with anti-Hsp 90 antibodies NZ552508A (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
GB0414885A GB0414885D0 (en) 2004-07-02 2004-07-02 Cancer therapy
GB0420845A GB0420845D0 (en) 2004-09-20 2004-09-20 Treatment of cancer
US61442304P 2004-09-30 2004-09-30
GB0503566A GB0503566D0 (en) 2005-02-21 2005-02-21 Treatment for cancer
US65445805P 2005-02-22 2005-02-22
PCT/GB2005/002545 WO2006003384A1 (en) 2004-07-02 2005-06-30 Treatment of cancer

Publications (1)

Publication Number Publication Date
NZ552508A true NZ552508A (en) 2009-10-30

Family

ID=39124615

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ552508A NZ552508A (en) 2004-07-02 2005-06-30 Treatment of cancer with pharmaceutical agents together with anti-Hsp 90 antibodies

Country Status (8)

Country Link
JP (1) JP2008504355A (es)
BR (1) BRPI0512889A (es)
EC (1) ECSP077219A (es)
IL (1) IL180460A (es)
MA (1) MA28701B1 (es)
MX (1) MX2007000263A (es)
NZ (1) NZ552508A (es)
SG (1) SG153877A1 (es)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0008305D0 (en) * 2000-04-06 2000-05-24 Neutec Pharma Plc Treatment of fungal infections

Also Published As

Publication number Publication date
MX2007000263A (es) 2007-07-20
BRPI0512889A (pt) 2008-04-15
SG153877A1 (en) 2009-07-29
ECSP077219A (es) 2007-03-29
JP2008504355A (ja) 2008-02-14
IL180460A (en) 2010-12-30
IL180460A0 (en) 2007-06-03
MA28701B1 (fr) 2007-06-01

Similar Documents

Publication Publication Date Title
AU2005259002B2 (en) Treatment of cancer
Viloria-Petit et al. Acquired resistance to EGFR inhibitors: mechanisms and prevention strategies
US20200069694A1 (en) Methods of treating metastatic breast cancer with trastuzumab-mcc-dm1
JP6525474B2 (ja) オーロラキナーゼ阻害剤と抗ｃｄ３０抗体の併用
ES2535404T5 (es) Uso de anticuerpo anti-VEGF en combinación con quimioterapia para tratar cáncer de mama
ES2904880T3 (es) Terapia combinada con inhibidores de Notch y de PD-1 o PD-L1
TW201032796A (en) Treatment of lung cancer with a PARP inhibitor in combination with a growth factor inhibitor
US9895439B2 (en) Combined treatment with netrin-1 interfering drug and chemotherapeutic drug
CN115135322A (zh) 包含哺乳动物雷帕霉素靶蛋白信号传导抑制剂作为有效成分的用于预防或治疗癌症的药物组合物
JP2017534574A (ja) チロシンキナーゼ阻害薬（ｔｋｉ）に耐性のがんを処置するための組成物および方法
US20220354961A1 (en) Methods of treating her2-positive metastatic breast cancer
WO2012111790A1 (ja) 化学療法剤の抗腫瘍活性増強剤
KR20140040728A (ko) Pi3k 억제제 화합물을 사용한 중피종 치료 방법
US20210213130A1 (en) Combination therapy with an anti-her2 antibody-drug conjugate and a bcl-2 inhibitor
WO2012106379A1 (en) Sensitization of cancer cells to treatment
WO2021057764A1 (zh) Pd-1抗体联合紫杉类化合物在制备治疗三阴性乳腺癌的药物中的用途
NZ552508A (en) Treatment of cancer with pharmaceutical agents together with anti-Hsp 90 antibodies
CN115227812A (zh) 抗pd-1抗体联合一线化疗治疗晚期nsclc的用途
WO2019129168A1 (zh) Pd-1抗体和阿帕替尼联合治疗三阴性乳腺癌的用途
US20230330243A1 (en) Combination of antibody-drug conjugate and atr inhibitor
US9801840B1 (en) Pharmaceutical composition and use thereof
KR102120223B1 (ko) 암의 예방 또는 치료용 의약 조성물
US20210060130A1 (en) Pharmaceutical compositions and use thereof for relieving anticancer drug resistance and enhancing sensitivity of anticancer drug
KR101941045B1 (ko) 암의 예방 또는 치료용 약학적 조성물
McNamara et al. Preclinical activity of datopotamab deruxtecan, a novel TROP2 directed antibody-drug conjugate targeting trophoblast cell-surface antigen 2 (TROP2) in ovarian carcinoma

Legal Events

Date Code Title Description
ASS Change of ownership

Owner name: NEUTEC PHARMA PLC, GB

Free format text: OLD OWNER(S): NEUTEC PHARMA PLC

RENW Renewal (renewal fees accepted)
PSEA Patent sealed
LAPS Patent lapsed